| Literature DB >> 15459178 |
Takeshi Hirota1, Ichiro Ieiri, Hiroshi Takane, Shinji Maegawa, Masakiyo Hosokawa, Kaoru Kobayashi, Kan Chiba, Eiji Nanba, Mitsuo Oshimura, Tetsuo Sato, Shun Higuchi, Kenji Otsubo.
Abstract
The human cytochrome P450 3A4 (CYP3A4) plays a dominant role in the metabolism of numerous clinically useful drugs. Alterations in the activity or expression of this enzyme may account for a major part of the variation in drug responsiveness and toxicity. However, it is generally accepted that most of the known single nucleotide polymorphisms in the coding and 5'-flanking regions are not the main determinants for the large inter-individual variability of CYP3A4 expression and activity. We show that the allelic variation is critically involved in determining the individual total hepatic CYP3A4 mRNA level and metabolic capability. There exists a definite correlation between the total CYP3A4 mRNA level and allelic expression ratio, the relative transcript level ratio derived from the two alleles. Individuals with a low expression ratio, exhibiting a large difference of transcript level between the two alleles, revealed extremely low levels of total hepatic CYP3A4 mRNA, and thus low metabolic capability as assessed by testosterone 6beta-hydroxylation. These results present a new insight into the individualized CYP3A4-dependent pharmacotherapy and the importance of expression imbalance to human phenotypic diversity.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15459178 DOI: 10.1093/hmg/ddh313
Source DB: PubMed Journal: Hum Mol Genet ISSN: 0964-6906 Impact factor: 6.150